Astellas Offloads Japan Product Basket To Private Equity Group
Executive Summary
Astellas has joined the growing ranks of research-based pharma firms offloading their older products in Japan, amid rising pricing and generic pressures and an increasing desire to focus on innovation.
You may also be interested in...
Deal Watch: United Therapeutics Looks To Extend PAH Dominance With Respira's Combo Product
United will finance clinical development of drug/inhaler device combo with Respira. Takeda offloads more mature products to its joint venture with Teva, and signs a microbiome partnership with Finch Therapeutics.
Deal Watch: Merck, Incyte Double Down On Keytruda/Epacadostat Collaboration
Expansion of 2015 development partnership adds lung and bladder cancer as well as renal and head-and-neck carcinoma to trials of the two immuno-oncology drugs. Jazz licenses Japanese rights to two of its commercial products to Nippon Shinyaku.
Sun Taps Mitsubishi For Ex-Novartis Japan Portfolio
Sun has now found a commercial partner in Japan for a bundle of mature products the Indian firm acquired from Novartis earlier this year, in an alliance expected to rapidly boost its presence in this key market and which some say might be expanded.